We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-8.24%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.44B
AUM Growth
-$537M
Cap. Flow
+$101M
Cap. Flow %
2.93%
Top 10 Hldgs %
35%
Holding
141
New
7
Increased
68
Reduced
12
Closed
10

Top Buys

Rank Stock Value
1
ALGN icon
Align Technology
ALGN
+$42.4M
2
PEN icon
Penumbra
PEN
+$31.3M
3
XLV icon
State Street Health Care Select Sector SPDR ETF
XLV
+$26.2M
4
HUM icon
Humana
HUM
+$25.7M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$18.1M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$94M
2
EHC icon
Encompass Health
EHC
+$35.7M
3
IRTC icon
iRhythm Holdings
IRTC
+$22M
4
XENT
Intersect ENT, Inc
XENT
+$15.4M
5
RIGL icon
Rigel Pharmaceuticals
RIGL
+$14.7M

Sector Composition

Rank Sector Weight
1 Healthcare 96.57%
2 Consumer Staples 0.96%
3 Industrials 0.47%
4 Financials 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LEGN icon
51
Legend Biotech
LEGN
$4B
$19.6M 0.57%
355,567
-55,617
-14% -$2.35M
CINC
52
DELISTED
CinCor Pharma, Inc. Common Stock
CINC
$19.2M 0.56%
1,021,159
-10,000
-1% -$191K
MRSN
53
DELISTED
Mersana Therapeutics
MRSN
$18.8M 0.55%
163,038
+12,805
+9% +$1.2M
AMLX icon
54
Amylyx Pharmaceuticals
AMLX
$2.53B
$18.8M 0.55%
974,107
-24,200
-2% -$287K
OLK
55
DELISTED
Olink Holding AB (publ) American Depositary Shares
OLK
$18.7M 0.54%
1,231,800
+245,800
+25% +$3.19M
PRTA icon
56
Prothena Corp
PRTA
$468M
$18.4M 0.54%
678,462
+14,932
+2% +$437K
RXDX
57
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
$18.2M 0.53%
644,507
+20,200
+3% +$585K
ACCD
58
DELISTED
Accolade Inc
ACCD
$16.3M 0.47%
2,200,000
+695,000
+46% +$6.08M
CYTK icon
59
Cytokinetics
CYTK
$10.5B
$15.7M 0.46%
+400,000
New +$16.1M
BCRX icon
60
BioCryst Pharmaceuticals
BCRX
$2.51B
$15.5M 0.45%
+1,461,091
New +$15.1M
KYMR icon
61
Kymera Therapeutics
KYMR
$9.03B
$15.3M 0.44%
775,879
+20,004
+3% +$467K
WRBY icon
62
Warby Parker
WRBY
$3.26B
$14.3M 0.42%
1,273,500
+235,000
+23% +$4.72M
AURA icon
63
Aura Biosciences
AURA
$796M
$14.3M 0.42%
1,008,814
+700
+0.1% +$11.6K
CMPX icon
64
Compass Therapeutics
CMPX
$400M
$14.1M 0.41%
5,328,088
– –
HCAT icon
65
Health Catalyst
HCAT
$127M
$13.7M 0.4%
945,400
+31,900
+3% +$544K
BMEA icon
66
Biomea Fusion
BMEA
$92.1M
$13M 0.38%
1,085,740
-79,842
-7% -$467K
COLL icon
67
Collegium Pharmaceutical
COLL
$882M
$12.8M 0.37%
725,000
– –
INZY
68
DELISTED
Inozyme Pharma
INZY
$12.6M 0.37%
2,640,056
+1,446,861
+121% +$6.29M
NVCR icon
69
NovoCure
NVCR
$2.02B
$12.2M 0.35%
175,000
– –
ARVN icon
70
Arvinas
ARVN
$588M
$11.8M 0.34%
280,100
-177,500
-39% -$8.91M
AZTA icon
71
Azenta
AZTA
$1.54B
$11.7M 0.34%
+162,000
New +$12.1M
ANAB icon
72
AnaptysBio
ANAB
$1.64B
$11.6M 0.34%
572,300
+9,000
+2% +$199K
LFST icon
73
Lifestance Health
LFST
$4.55B
$11.1M 0.32%
2,000,000
– –
EPZM
74
DELISTED
Epizyme, Inc
EPZM
$11M 0.32%
7,485,543
+217,847
+3% +$160K
FOLD
75
DELISTED
Amicus Therapeutics
FOLD
$10.9M 0.32%
1,012,506
– –
1 2
3
4 5

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q2 2022 Portfolio in Review

As of Q2 2022, Rock Springs Capital Management held 141 positions worth $3.44B, down 14% from $3.97B the previous quarter. Its ten largest holdings account for 35% of the portfolio.

Rock Springs Capital Management's Q2 2022 filing shows 7 new, 68 increased, 12 reduced and 10 closed positions. Its largest new stake was State Street Health Care Select Sector SPDR ETF: 200,000 shares worth $25.6M. The largest sale was HCA Healthcare, an estimated $94M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 95% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q2 2022 buy was State Street Health Care Select Sector SPDR ETF: 200,000 shares worth $25.6M.
  • Rock Springs Capital Management added most to Align Technology in Q2 2022, an estimated $42.4M increase.
  • Rock Springs Capital Management's biggest Q2 2022 reduction was iRhythm Holdings, cutting an estimated $22M.
  • Rock Springs Capital Management fully exited HCA Healthcare in Q2 2022, selling an estimated $94M.
  • Rock Springs Capital Management's ten largest holdings make up 35% of its $3.44B portfolio in Q2 2022.
  • Rock Springs Capital Management opened 7 new positions and closed 10 in Q2 2022.
  • Rock Springs Capital Management's portfolio value fell 14% quarter-over-quarter to $3.44B.

Based on Rock Springs Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.